BIOAGE Labs
BIOA · NASDAQ
$5.56+$0.57 (+11.42%)TodayMarket closed ·
Prev close $4.99
About BIOA
- Employees
- 60
- Headquarters
- Emeryville, California
- Listed
- Sep 26, 2024
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Website
- bioagelabs.com
BIOA key statistics
- Market cap
- 229.03M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 891.27K
- Volume
- 1.20M
- Open price
- $5.00
- High today
- $5.64
- Low today
- $4.97
- 52 Week high
- $25.96
- 52 Week low
- $4.81
BIOAGE Labs (BIOA) at a glance
BIOAGE Labs (BIOA) last traded at $5.56, with a market cap of 229.03M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $4.97 and $5.64. The current price is 11.9% above the day's low and 1.4% below its high.
Volume so far is 1.20M shares, above the average of 891.27K shares a day.
Over the past year BIOAGE Labs has ranged from $4.81 to $25.96, and now sits 4% of the way up that range.
BIOAGE Labs met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.58 per share against an estimate of -$0.6242.
The average analyst price target is $36.34, 553.6% above the current price, from 9 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
78%of 9 analyst ratings say Buy
- Buy77.8%
- Hold22.2%
- Sell0.0%
Price target · 10 analystsAvg $36.34
- Low
- $20.20
- Now
- $5.56
- High
- $76.65
BIOA earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 6 of the last 8 quarters, by 13.0% on average.
- Q3 FY24: reported -$6.70 per share against an estimate of -$0.7362
- Q4 FY24: reported -$1.97 per share against an estimate of -$2.12
- Q1 FY25: reported -$0.36 per share against an estimate of -$0.5392
- Q2 FY25: reported -$0.60 per share against an estimate of -$0.4904
- Q3 FY25: reported -$0.56 per share against an estimate of -$0.5959
- Q4 FY25: reported -$0.72 per share against an estimate of -$0.7536
- Q1 FY26: reported -$0.52 per share against an estimate of -$0.6528
- Q2 FY26: reported -$0.58 per share against an estimate of -$0.6242
BIOA news
- Press releasePRNewswire
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
- Press releaseGlobe Newswire
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Vandana Singh
Why Is BioAge Labs Stock Sinking Friday?
- Avi Kapoor
Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releasePRNewswire
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- Press releasePRNewswire
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Similar companies
Companies in the same industry as BIOAGE Labs
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.